Phase 3 Study of Niraparib-Plus-Pembrolizumab as Maintenance Therapy for Advanced/Metastatic Non-Small Cell Lung Cancer (ZEAL-1L).
Suresh S Ramalingam, Vamsidhar Velcheti, Mehmet Altan, Gilberto de Castro, Michael Thomas, Rachel E Sanborn, Julien Maziéres, Martin Schuler, Johan Isaksson, Michael Schenker, Elena Poddubskaya, Yu Jung Kim, Sagun Parakh, Wenlei Liu, Melissa Whipple Neibauer, Vishvajit Aghera, Gavin Chiu, Solange Peters
J Thorac Oncol 104087
摘要
摘要
INTRODUCTION: This randomized, double-blind, phase 3 study evaluated niraparib-plus-pembrolizumab as maintenance therapy for patients with advanced/metastatic non-small cell lung cancer (NSCLC; ZEAL-1L, ClinicalTrials.gov identifier: NCT04475939). METHODS: Adults with advanced/metastatic squamous/nonsquamous NSCLC without known targetable driver alteration were randomly assigned (1:1) to receive niraparib-plus-pembrolizumab or placebo-plus-pembrolizumab as maintenance therapy. Niraparib was given as a daily oral dose of 300 mg, and intravenous pembrolizumab was administered at 200 mg every 3 weeks. The primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR) in patients with complete or partial response (CR/PR) to front-line chemotherapy combined with pembrolizumab. Hierarchical testing was performed on the primary and key secondary endpoints in a prespecified sequential order; formal testing was stopped if any endpoint failed to reach statistical significance. RESULTS: Patients comprising the intent-to-treat (ITT) population (n=666) were randomly assigned to niraparib-plus-pembrolizumab (n=331) or placebo-plus-pembrolizumab (n=335) therapy. The median PFS for the CR/PR population (n=200 receiving niraparib-plus-pembrolizumab; n=201 receiving placebo-plus-pembrolizumab) was 5.55 months for both treatment arms (hazard ratio [HR], 1.00; 95% CI, 0.79-1.27; 1-sided p=0.502). Key secondary endpoints of PFS by BICR in the ITT population, overall survival in CR/PR and ITT populations, and time to progression in the central nervous system were not formally tested. The most common grade ≥3 treatment-related adverse events for the niraparib-plus-pembrolizumab arm were hematologic (anemia, thrombocytopenia, and neutropenia). CONCLUSION: The addition of niraparib to pembrolizumab for maintenance therapy in patients with advanced/metastatic NSCLC did not result in improved efficacy; no new safety signals were detected. CLINICAL TRIAL INFORMATION: ClinicalTrials.gov Identifier: NCT04475939.
KM 提取结果
0 个 Figure · 0 个 KM 面板